MissionIR Articles
-
Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery
Strengthening IP for Long-Term Market Protection Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark…
-
Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and…
-
Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector
Strategic alliances are vital to success in the pharmaceutical sector, where innovation, regulatory navigation and market access are complex and resource-intensive. Collaborations between biotech firms, research institutions and major pharmaceutical companies accelerate drug development, reduce…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has been granted a patent in Macao for its AVERSA™ abuse-deterrent transdermal technology. The patent, titled “Abuse and Misuse Deterrent Transdermal Systems,” was granted on…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology
Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product
Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports on Share Repurchase Program
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has authorized a share repurchase program to buy back up to $1 million of its common stock. According to the announcement, as of Sept. 16, 2024,…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q1 2024 Quarterly Report
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, is reporting its first-quarter 2024 revenues. According to the report, the company saw revenues of $408,532 while also strengthening its balance sheet with the completion…
-
MissionIRNewsBreaks – Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. “The company’s AVERSA(TM) can be incorporated into any transdermal patch and includes aversive agents to prevent misuse and accidental exposure…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, will be spotlighted in an upcoming webinar, hosted by RedChip Companies. The event is slated for May 30, 2024, and will begin at 4:15 p.m.…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Names Seasoned Business Leader to Board of Directors
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical solutions, has announced a new member of its board of directors. According to the announcement, Sergei Glinka, a seasoned and highly respected business executive, will serve on…
-
Fentanyl Scourge: Nutriband Inc.’s (NASDAQ: NTRB) New Transdermal Patch with Abuse-Deterrent Tech Funded to Seek FDA Approval
Fentanyl addiction continues to devastate communities, with current treatment options facing limitations. However, as often happens in healthcare, innovation breeds hope with a new option on the horizon planning to seek FDA marketing approval. The…
-
Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic
Fentanyl, a potent opioid, poses a significant problem due to its potential for abuse with a high risk of overdose – even in small quantities. Nutriband (NASDAQ: NTRB) is advancing its AVERSA(TM) technology that features aversive agents…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Enters Into Private Placement Agreements to Raise Funds for Development of AVERSA Fentanyl
Nutriband (NASDAQ: NTRB), a company engaged in the development of abuse-deterrent pharmaceutical products, has entered into definitive securities purchase agreements. The agreements are for the purchase and sale of up to 2,100,000 shares of common…
-
Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Demonstrates AI Drone Threat Detection in U.S. Army Live Fire Exercise
- MissionIRNewsBreaks – Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement
- MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Enters Strategic Cooperation With AIBO Robotics to Advance AI-Driven Automation and Smart Mobility
- Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications